Covalent binding of carbamazepine reactive metabolites to P450 isoforms present in the skin

Chemico-Biological Interactions

Volumn 113, Issue 1, 1998, Pages 39-50

  Wolkenstein, Pierre ^a   Tan, Chanthavy ^b   Lecoeur, Sylvaine ^b   Wechsler, Janine ^a   Garcia Martin, Nadine ^a   Charue, Dominique ^a   Bagot, Martine ^a   Beaune, Philippe ^b  

^a HENRI MONDOR HOSPITAL   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Carbamazepine; Cytochrome P450 1A2; Cytochrome P450 3A4; Hypersensitivity; Reactive metabolites; Skin

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CYTOCHROME P450; DRUG METABOLITE;

ARTICLE; CONTROLLED STUDY; COVALENT BOND; DRUG METABOLISM; ENZYME BINDING; EPIDERMIS; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERSENSITIVITY REACTION; LIVER MICROSOME; NONHUMAN; PROTEIN EXPRESSION; YEAST;

ADULT; ANTICONVULSANTS; CARBAMAZEPINE; CYTOCHROME P-450 ENZYME SYSTEM; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; HUMANS; KINETICS; MALE; METABOLIC DETOXICATION, DRUG; MICROSOMES, LIVER; MIDDLE AGED; RECOMBINANT PROTEINS; SACCHAROMYCES CEREVISIAE; SKIN;

STAPHYLOCOCCUS PHAGE 3A;

EID: 0031866703     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(98)00021-0     Document Type: Article

References (30)

1. Roujeau J.-C., Kelly J.P., Naldi L., Rzany B., Stern R.S., Anderson T., Auquier A., Bastuji-Garin S., Correia O., Locati F., Mockenhaupt M., Paoletti C., Shapiro S., Shear N., Schöpf E., Kaufman D.W. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. New. Engl. J. Med. 333:1995;1600-1607.
2. Kerr B.M., Thummel K.E., Wurden C.J., Klein S.M., Kroetz D.L., Gonzalez F.J., Levy R.H. Human liver carbamazepine metabolism: role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem. Pharmacol. 47:1994;1969-1979.
3. Madden S., Maggs J.L., Park B.K. Bioactivation of carbamazepine in the rat in vivo, evidence for the formation of reactive arene oxide(s). Drug. Metab. Dispos. 24:1996;469-479.
4. Lillibridge J.H., Amore B.M., Slattery J.T., Kalhorn T.F., Nelson S.D., Finnell R.H., Bennett G.D. Protein-reactive metabolites of carbamazepine in mouse liver microsomes. Drug. Metab. Dispos. 24:1996;509-514.
5. Shear N.H., Spielberg S.P. Anticonvulsant hypersensitivity syndrome. J. Clin. Invest. 82:1988;1826-1832.
6. Wolkenstein P., Charue D., Laurent Ph., Revuz J., Roujeau J.-C., Bagot M. Metabolic predisposition to cutaneous adverse drug reactions: role in toxic epidermal necrolysis caused by sulfonamides and anticonvulsants. Arch. Dermatol. 131:1995;544-551.
7. Pirmohamed M., Kitteringham N.R., Breckenridge A.M., Park B.K. The effect of enzyme induction on the cytochrome P450-mediated bioactivation of carbamazepine by mouse liver microsomes. Biochem. Pharmacol. 44:1992;2307-2314.
8. Leeder J.S., Riley R.J., Cook V.A., Spielberg S.P. Human anti-cytochrome P450 antibodies in aromatic anticonvulsant-induced hypersensitivity reactions. J. Pharmacol. Exp. Ther. 263:1992;267-360.
9. Riley R.J., Smith G., Wolf C.R., Cook V.A., Leeder J.S. Human anti-endoplasmic reticulum autoantibodies produced in aromatic anticonvulsant hypersensitivity reactions recognise rodent CYP3A proteins and a similarly regulated human P450 enzyme(s). Biochem. Biophys. Res. Commun. 19:1993;32-40.
10. Leeder J.S., Gaedigk A., Lu X.L., Cook V.A. Epitope mapping studies with human anti-cytochrome P450 3A antibodies. Mol. Pharmacol. 49:1996;234-243.
11. Lecoeur S., Bonierbale E., Challine D., Gautier J.C., Valadon Ph., Dansette D.M., Catinot R., Ballet F., Mansuy D., Beaune Ph. Specificity of in vitro covalent binding of tienilic acid metabolites to human liver microsomes in relationship to the type of hepatotoxicity: comparison with two directly hepatotoxic drugs. Chem. Res. Toxicol. 7:1994;434-442.
12. Kremers P., Beaune Ph., Cresteil T., De Greave J., Columelli S., Leroux J.P., Gielen J.E. Cytochrome P450 monooxygenase activities in human and rat liver microsomes. Eur. J. Biochem. 118:1981;599-606.
13. Schoene B., Fleischman R.A., Remmer H., Van Oldershausen H.F. Determination of drug metabolizing enzymes in needle biopsies of human liver. Eur. J. Clin. Pharmacol. 4:1972;65-73.
14. Shimada T., Misono K.S., Guengerich F.P. Human liver microsomal cytochrome P450 mephenytoine 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 261:1986;909-921.
15. Beaune Ph., Kremers P., Letawe-Goujon F., Gielen J.E. Monoclonal antibodies against human liver cytochrome P-450. Biochem. Pharmacol. 34:1985;3547-3552.
16. Dansette P., Amar C., Valadon P., Pons C., Beaune Ph., Mansuy D. Hydroxylation and formation of electrophilic metabolites of tienilic acid and its isomer by human liver microsomes. Catalysis by a cytochrome P450 II C different from that responsible for mephenytoin hydroxylation. Biochem. Pharmacol. 41:1991;553-560.
17. Wallin H., Schelin C., Tunek A., Jergil B. A rapid and sensitive method for determination of covalent binding of benzo-(a)pyrene to proteins. Chem.-Biol. Interact. 38:1981;109-118.
18. Laemmli U.K. Cleavage of structural properties during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
19. Towbin H., Steahelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA. 76:1979;4350-4354.
20. Guenguerich F.P., Turvy C.G. Comparison of levels of several human microsomal P450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J. Pharmacol. Exp. Ther. 256:1991;1189-1194.
21. Goldstein J.A., Faletto M.B., Raucy J.L., Lasker J.M., Romkes-Sparks M. Metabolism of S-mephenytoin by the human P450 2C subfamily. J. Basic Clin. Physiol. Pharmacol. 3(Suppl. 0):1992;128.
22. Smith D.A. Species differences in metabolism and pharmacokinetics: are we close to an understanding? Drug Metab. Rev. 23:1991;355-373.
23. Bourdi M., Gautier J.C., Mircheva J., Larrey D., Guillouzo A., André C., Belloc C., Beaune Ph. Anti-liver microsomes autoantibodies and dihydralazine-induced hepatitis: specificity of autoantibodies and inductive capacity of the drug. Mol. Pharmacol. 42:1992;280-285.
24. Liu H., Delgado M.R. Interactions of phenobarbital and phenytoin with carbamazepine and its metabolites concentrations, concentration ratios and level/dose ratios in epileptic children. Epilepsia. 36:1995;249-254.
25. Jugert F.K., Agarwal R., Kuhn A., Bickers D.R., Merk H.F., Mukhtar H. Multiple cytochrome 450 isoenzymes in murine skin: induction of P450 1A, 2B, 2E and 3A by dexamethasone. J. Invest. Dermatol. 102:1994;970-975.
26. Khan W.A., Park S.S., Gelboin H.V., Bickers D.R., Mukhtar H. Monoclonal antibodies directed characterisation of epidermal and hepatic cytochrome P-450 isoenzymes induced by skin application of therapeutic crude coaltar. J. Invest. Dermatol. 93:1989;40-45.
27. Van Pelt F.N., Olde Meierink Y.J., Blaauboer B.J., Weterings P.J. Immunohistochemical detection of cytochrome 450 isoenzymes in cultured human epidermal cells. J. Histochem. Cytochem. 38:1990;1847-1851.
28. Vecchini F., Mace K., Magdalou J., Mahe Y., Bernard B.A., Shroot B. Constitutive and inducible expression of drug metabolizing enzymes in cultured human keratinocytes. Br. J. Dermatol. 132:1995;14-21.
29. Hirel B., Chesne C., Pailheret J.P., Guillouzo A. In vitro expression of drug metabolizing enzyme activities in human adult keratinocytes under various culture conditions and their response to inducers. Toxicol. Vitro. 9:1995;49-56.
30. Hirel B., Watier E., Chesne C., Patoux-Pibouin M., Guillouzo A. Culture and drug biotransformation capacity f adult human keratinocytes from post-mortem skin. Br. J. Dermatol. 134:1996;831-836.